Document is current
Any future updates will be listed below
-
Authors
Mäki-Heikkilä, Rikhard https://orcid.org/0000-0002-9658-4607
Karjalainen, Jussi https://orcid.org/0000-0001-8747-7087
Parkkari, Jari https://orcid.org/0000-0001-5211-9845
Valtonen, Maarit https://orcid.org/0000-0001-8883-2255
Lehtimäki, Lauri https://orcid.org/0000-0003-1586-4998
-
Funding
Funding for this research was provided by:
Tampere Tuberculosis Foundation
- License Information
-
More Information
Article History
First Online: 11 September 2020
Compliance with Ethical Standards
:
: The study was supported by the Tampere Tuberculosis Foundation.
: Mr Mäki-Heikkilä declares receiving financial support from Tampere Tuberculosis Foundation and Tampere University to author this publication. Dr Karjalainen declares receiving grant from Tampere Tuberculosis Foundation, fees for consulting from Boehringer Ingelheim, Finnish Center for Integrity in Sports, GlaxoSmithKline, Merck Sharp & Dohme, Novartis and Teva and payments for lectures from ALK, AstraZeneca, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Leo Pharma, Mundipharma, Novartis and Orion Pharma. Dr Parkkari declares no conflicts of interest. Dr Valtonen declares employment for acting as team doctor for Finnish Ski Association via KIHU – Research Institute for Olympic Sports. Dr Lehtimäki declares having received fees for consulting from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Orion Pharma, Mundipharma, Novartis, SanofiGenzyme and Teva, and payments for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, GSK, Orion Pharma, Mundipharma, Novartis, SanofiGenzyme and Teva.
: The search syntax used in this review is available as Supplemental file 1, the detailed risk of bias assessment is available as Supplemental file 2 and the full-text search with exclusion reasons is available as Supplemental file 3. The data extraction table is available from authors on reasonable request.
